Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Allen W. Ho, Evdoxia Hatjiharissi, Bryan T. Ciccarelli, Andrew R. Branagan, Zachary R. Hunter, Xavier Leleu, Olivier Tournilhac, Lian Xu, Kelly O'Connor, Robert J. Manning, Daniel Ditzel Santos, Mariana Chemaly, Christopher J. Patterson, Jacob D. Soumerai, Nikhil C. Munshi, Julie A. McEarchern, Che-Leung Law, Iqbal S. Grewal, Steven P. Treon

Blood (2008) 112 (12): 4683–4689.

https://doi.org/10.1182/blood-2007-04-084525

Published: 2008

Journal Articles

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

Evdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, Zachary R. Hunter, Bryan T. Ciccarelli, Sigitas Verselis, Michael Modica, Yang Cao, Robert J. Manning, Xavier Leleu, Elizabeth A. Dimmock, Alexandros Kortsaris, Constantine Mitsiades, Kenneth C. Anderson, Edward A. Fox, Steven P. Treon

Blood (2007) 110 (7): 2561–2564.

https://doi.org/10.1182/blood-2007-01-070656

Published: 2007

Journal Articles

Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab.

Evdoxia Hatjiharissi, MD, Daniel Ditzel Santos, MD, Lian Xu, Sigitas Verselis, PhD, Michael Modica, PhD, Xavier Leleu, MD, Zachary Hunter, Allen W. Ho, Robert Manning, Christopher Patterson, Kenneth C. Anderson, MD, Edward Fox, PhD, Steven P. Treon, MD, PhD

Blood (2005) 106 (11): 776.

https://doi.org/10.1182/blood.V106.11.776.776

Published: 2005

Journal Articles

Polymorphisms in Fc γ RIIIA Are Genetically Linked to FcγRIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcγRIIIA-158 in Determining Rituximab Responses.

Evdoxia Hatjiharissi, MD, Mark Hansen, Sigitas Verselis, PhD, Daniel Ditzel Santos, MD, Lian Xu, Robert Manning, Zachary Hunter, Xavier Leleu, MD, Allen W. Ho, Christopher J. Patterson, Edward Fox, PhD, Steven P. Treon, MD, PhD

Blood (2005) 106 (11): 2433.

https://doi.org/10.1182/blood.V106.11.2433.2433

Published: 2005

Journal Articles

Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom’s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.

Daniel Ditzel Santos, MD, Mariana Z.A. Chemaly, MD, Olivier Tournilhac, MD, Kelly E. OConnor, Evdoxia Hatjiharissi, MD, Xavier Leleu, MD, Lian Xu, Andrew R. Branagan, Robert J. Manning, Christopher Patterson, Allen W. Ho, Zachary R. Hunter, James M. You, MD. Phd, Yu-Tzu Tai, Phd, Jeffery L. Kutok, Kenneth C. Anderson, Nikhil Munshi, Steven P. Treon

Blood (2005) 106 (11): 980.

https://doi.org/10.1182/blood.V106.11.980.980

Published: 2005

Journal Articles

Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.

Blood (2005) 106 (11): 979.

https://doi.org/10.1182/blood.V106.11.979.979

Published: 2005

Journal Articles

A SCID-hu in vivo model of human Waldenström macroglobulinemia

Pierfrancesco Tassone, Paola Neri, Jeffery L. Kutok, Olivier Tournilhac, Daniel Ditzel Santos, Evdoxia Hatjiharissi, Vidit Munshi, Salvatore Venuta, Kenneth C. Anderson, Steven P. Treon, Nikhil C. Munshi

Blood (2005) 106 (4): 1341–1345.

https://doi.org/10.1182/blood-2004-11-4477

Published: 2005

Journal Articles

Clinical Responses to Sildenafil in Waldenstrom’s Macroglobulinemia.

Steven P. Treon, Olivier Tournilhac, Andrew Branagan, Zachary Hunter, Lian Xu, Evdoxia Hatjiharissi, Daniel Ditzel Santos

Blood (2004) 104 (11): 4926.

https://doi.org/10.1182/blood.V104.11.4926.4926

Published: 2004

Journal Articles

Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.

Olivier Tournilhac, Daniel Ditzel Santos, Lian Xu, Evdoxia Hatjiharissi, Yu Tsu, Tai, Laurie Catley, Zachary Hunter, Andrew Branagan, Renate Burger, Reshma Shringarpure, Joshua Boyce, Kenneth C. Anderson, Steven P. Treon

Blood (2004) 104 (11): 4929.

https://doi.org/10.1182/blood.V104.11.4929.4929

Published: 2004

Journal Articles

A Novel Murine Model for Human Waldenstrom’s Macroglobulinemia.

Pierfrancesco Tassone, MD, Paola Neri, MD, Jeffery Kutok, MD, Olivier Tournilhac, MD, Daniel Ditzel Santos, MD, Evdoxia Hatjiharissi, MD, Salvatore Venuta, MD, PhD, Kenneth C. Anderson, MD, Steven Treon, MD, Nikhil C. Munshi, MD

Blood (2004) 104 (11): 3646.

https://doi.org/10.1182/blood.V104.11.3646.3646

Published: 2004

Journal Articles

B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.

Daniel Ditzel Santos, Olivier Tournilhac, Lian Xu, Hatjiharrisi Evdoxia, Zachary Hunter, Andrew Branagan, Robert Manning, Kenneth C. Anderson, Iqbal Grewal, Steven P. Treon

Blood (2004) 104 (11): 3358.

https://doi.org/10.1182/blood.V104.11.3358.3358

Published: 2004

Journal Articles

Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstrom’s Macroglobulinemia.

Oliver Tournilhac, Steven Le Gouill, Daniel Ditzel Santos, Klaus Podar, Lian Xu, Evdoxia Hatjiharissi, Yu-Tzu Tai, Zachary Hunter, Andrew Branagan, Kenneth C. Anderson, Steven P. Treon

Blood (2004) 104 (11): 4892.

https://doi.org/10.1182/blood.V104.11.4892.4892

Published: 2004

Journal Articles

IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstrom’s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions.

Steven Treon, Andrew Branagan, Zachary Hunter, Daniel Ditzel Santos, Olivier Tournilhac, Evdoxia Hatjiharissi, Lian Xu, Robert Manning

Blood (2004) 104 (11): 4896.

https://doi.org/10.1182/blood.V104.11.4896.4896

Published: 2004

Journal Articles

Constitutive Expression of CD40L on Bone Marrow Mast Cells Supports the Growth of Lymphoplasmacytic Cells in Patients with Waldenstrom’s Macroglobulinemia.

Olivier Tournilhac, Daniel Ditzel Santos, Lian Xu, Jeffery Kutok, Yu Tsu Tai, Steven Le Gouill, Evdoxia Hatjiharissi, Laurie Catley, Zachary Hunter, Andrew Branagan, Kenneth C. Anderson, Steven P. Treon

Blood (2004) 104 (11): 2350.

https://doi.org/10.1182/blood.V104.11.2350.2350

Published: 2004

Journal Articles

High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenströM’s Macroglobulinemia.

Zachary R. Hunter, Andrew R. Branagan, Daniel Ditzel Santos, Olivier Tournilhac, Evdoxia Hatjiharissi, Lian Xu, Robert J. Manning, Steven P. Treon

Blood (2004) 104 (11): 4881.

https://doi.org/10.1182/blood.V104.11.4881.4881

Published: 2004

Journal Articles

CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders.

Daniel Ditzel Santos, Evdoxia Hatjiarissi, Olivier Tournilhac, Lian Xu, Andrew Branagan, Zachary Hunter, Mayan Catsells, Kenneth C. Anderson, Steven P. Treon

Blood (2004) 104 (11): 4885.

https://doi.org/10.1182/blood.V104.11.4885.4885

Published: 2004

Journal Articles

Thalidomide and Rituximab in Waldenström’s Macroglobulinemia.

Andrew Branagan, Zachary Hunter, Daniel Ditzel Santos, Steven P. Treon

Blood (2004) 104 (11): 1484.

https://doi.org/10.1182/blood.V104.11.1484.1484

Published: 2004

NARROW

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab.

Polymorphisms in Fc γ RIIIA Are Genetically Linked to FcγRIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcγRIIIA-158 in Determining Rituximab Responses.

Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom’s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.

Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.

A SCID-hu in vivo model of human Waldenström macroglobulinemia

Clinical Responses to Sildenafil in Waldenstrom’s Macroglobulinemia.

Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.

A Novel Murine Model for Human Waldenstrom’s Macroglobulinemia.

B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.

Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstrom’s Macroglobulinemia.

IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstrom’s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions.

Constitutive Expression of CD40L on Bone Marrow Mast Cells Supports the Growth of Lymphoplasmacytic Cells in Patients with Waldenstrom’s Macroglobulinemia.

High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenströM’s Macroglobulinemia.

CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders.

Thalidomide and Rituximab in Waldenström’s Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only